Swiss Life Asset Management Ltd Buys 1,721 Shares of Thermo Fisher Scientific Inc. $TMO

Swiss Life Asset Management Ltd increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 46,801 shares of the medical research company’s stock after acquiring an additional 1,721 shares during the period. Swiss Life Asset Management Ltd’s holdings in Thermo Fisher Scientific were worth $27,119,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Sentry Investment Management LLC lifted its stake in shares of Thermo Fisher Scientific by 4.3% during the 4th quarter. Sentry Investment Management LLC now owns 987 shares of the medical research company’s stock worth $572,000 after acquiring an additional 41 shares during the last quarter. Byrne Financial Freedom LLC raised its position in Thermo Fisher Scientific by 7.9% during the 4th quarter. Byrne Financial Freedom LLC now owns 1,505 shares of the medical research company’s stock valued at $872,000 after purchasing an additional 110 shares in the last quarter. Drive Wealth Management LLC bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at $251,000. Pure Financial Advisors LLC raised its position in Thermo Fisher Scientific by 6.2% during the 4th quarter. Pure Financial Advisors LLC now owns 1,407 shares of the medical research company’s stock valued at $815,000 after purchasing an additional 82 shares in the last quarter. Finally, Osprey Private Wealth LLC raised its position in Thermo Fisher Scientific by 17.0% during the 4th quarter. Osprey Private Wealth LLC now owns 19,140 shares of the medical research company’s stock valued at $11,091,000 after purchasing an additional 2,780 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $63,499,170. The trade was a 3.88% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on TMO shares. Morgan Stanley reaffirmed an “overweight” rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Stifel Nicolaus cut their price target on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, April 24th. UBS Group reiterated a “neutral” rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. DZ Bank initiated coverage on Thermo Fisher Scientific in a report on Friday, March 27th. They issued a “buy” rating and a $610.00 price target on the stock. Finally, Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $619.65.

Thermo Fisher Scientific Stock Down 2.8%

Shares of TMO stock opened at $452.14 on Tuesday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The stock’s fifty day moving average price is $491.19 and its 200 day moving average price is $545.39. The company has a market cap of $168.02 billion, a price-to-earnings ratio of 24.86, a price-to-earnings-growth ratio of 2.06 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Friday, March 13th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.